nach oben

Erschienen in:

01.09.2010 | Original Article

Serum levels of proamylin and amylin in normal subjects and patients with impaired glucose regulation and type 2 diabetes mellitus

verfasst von: Xiaoya Zheng, Wei Ren, Suhua Zhang, Jingjing Liu, Sufang Li, Jinchao Li, Ping Yang, Jun He, Shaochu Su, Ping Li

Erschienen in: Acta Diabetologica | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Amylin is the major constituent of pancreatic islet amyloid whose accumulation characterizes patients with type 2 diabetes mellitus (T2DM). Although amylin is tightly linked with T2DM, in many cases, proamylin may be the more toxic species. As the precursor of amylin, however, the pathophysiological role of proamylin remains unknown. In this study, we investigate whether serum levels of proamylin or amylin or the proamylin/amylin ratios are different among normal subjects and patients with impaired glucose regulation (IGR) and T2DM. Totally 79 subjects were divided into three groups according to the results of oral glucose tolerance test (OGTT); they were T2DM group (32 cases), IGR group (23cases), and normal glucose tolerance (NGT) group (24cases). Serum levels of amylin and proamylin were measured with an enzyme-linked immunosorbent assay (ELISA). The relationships between serum levels of proamylin, amylin, their ratios and anthropometric and metabolic parameters were also analyzed. The serum levels of proamylin were significantly higher in patients with IGR and T2DM than in control subjects. The serum levels of proamylin were significantly associated with IGR and T2DM, with the odds ratios of 1.589 (95%CI, 1.228–2.055, P < 0.01) and 1.860 (95%CI, 1.342–2.587, P < 0.01), respectively. Both fasting serum levels of proamylin and proamylin/amylin ratios were found to correlate negatively with HOMA-B and ΔI30/ΔG30. Serum levels of proamylin, amylin, and their ratios were positively correlated with HOMA-IR. BMI and HOMA-B were independent related factors with serum levels of proamylin. Our results suggest that proamylin may play an important role in amyloid deposit in patients with IGR and T2DM.

Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3–19CrossRefPubMed

Manco M, Giordano U, Turchetta A et al (2009) Insulin resistance and exercise capacity in male children and adolescents with non-alcholic fatty liver disease. Acta Diabetol 46(2):97–104CrossRefPubMed

Butler AE, Janson J, Bonner-Weir S et al (2003) β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110CrossRefPubMed

Ruchat SM, Elks CE, Loos RJ et al (2009) Association between insulin secretion, insulin sensitivity and type 2 diabetes susceptibility variants identified in genome-wide association studies. Acta Diabetol 46(3):217–226CrossRefPubMed

Rhodes CJ (2005) Type 2 diabetes: a matter of beta-cell life and death? Science 307:380–384CrossRefPubMed

Chistiakov DA, Potapov VA, Khodirev DC et al (2009) Genetic variations in the pancreatic ATP-sensitive potassium channel, beta-cell dysfunction, and susceptibility to type 2 diabetes. Acta Diabetol 46(1):43–49CrossRefPubMed

Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241–253CrossRefPubMed

Clark A, Nilsson MR (2004) Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes? Diabetologia 47:157–169CrossRefPubMed

Federici M, Hribal M, Perego L et al (2001) High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 50(6):1290–1301CrossRefPubMed

10.

Chisalita SI, Lindström T, Eson Jennersjö P et al (2009) Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control. Acta Diabetol 46(1):35–42CrossRefPubMed

11.

Hartter E, Svoboda T, Ludvik B et al (1991) Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34:52–54CrossRefPubMed

12.

Kahn SE, D’Alessio DA, Schwartz MW et al (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by beta cells. Diabetes 39:634–638CrossRefPubMed

13.

Clark A, Charge SB, Badman MK et al (1996) Islet amyloid polypeptide: actions and role in the pathogenesis of diabetes. Biochem Soc Trans 24:594–599PubMed

14.

Guardado-Mendoza R, Davalli AM, Chavez AO, et al (2009) Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci 18; 106(33):13992–13997

15.

Huang CJ, Lin CY, Haataja L et al (2007) High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56(8):2016–2027CrossRefPubMed

16.

Butler AE, Janson J, Soeller WC et al (2003) Increased beta cell apoptosis prevents adaptive increase in beta cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52:2304–2314CrossRefPubMed

17.

Butler AE, Jang J, Gurlo T et al (2004) Diabetes due to a progressive defect in beta cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes. Diabetes 53:1509–1516CrossRefPubMed

18.

Zraika S, Hull RL, Udayasankar J et al (2009) Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. Diabetologia 52(4):626–635CrossRefPubMed

19.

Matveyenko AV, Gurlo T, Daval M et al (2009) Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced beta-cell endoplasmic reticulum stress. Diabetes 58(4):906–916CrossRefPubMed

20.

Porte D Jr, Kahn SE (1989) Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β-cell dysfunction? Diabetes 38:1333–1336CrossRefPubMed

21.

Westermark P, Engstrom U, Westermark GT et al (1989) Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans. Diabetes Res Clin Pract 7:219–226CrossRefPubMed

22.

Hou X, Ling Z, Quartier E et al (1999) Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors. Diabetologia 42:188–194CrossRefPubMed

23.

Marzban L, Rhodes CJ, Steiner DF et al (2006) Impaired NH2-terminal processing of human proislet amyloid polypeptide by the prohormone convertase PC2 leads to amyloid formation and cell death. Diabetes 55(8):2192–2201CrossRefPubMed

24.

Wang J, Xu J, Finnerty J et al (2001) The prohormone convertase enzyme 2 (PC2) is essential for processing pro-islet amyloid polypeptide at the NH2-terminal cleavage site. Diabetes 50(3):534–539CrossRefPubMed

25.

Marzban L, Park K, Verchere CB (2003) Islet amyloid polypeptide and type 2 diabetes. Exp Gerontol 38:347–351CrossRefPubMed

26.

Krampert M, Bernhagen J, Schmucker J et al (2000) Amyloidogenicity of recombinant human proislet amyloid polypeptide (ProIAPP). Chem Biol 7:855–871CrossRefPubMed

27.

Paulsson JF, Andersson A, Westermark P et al (2006) Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets. Diabetologia 49:1237–1246CrossRefPubMed

28.

Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. 1. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetes Med 15:539–553CrossRef

29.

Jha S, Sellin D, Seidel R, et al (2009) Amyloidogenic propensities and conformational properties of ProIAPP and IAPP in the presence of lipid bilayer membranes. J Mol Biol 26; 389(5):907–920

30.

Hull RL, Westermark GT, Westermark P et al (2004) Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 89:3629–3643CrossRefPubMed

31.

Alarcon C, Leahy JL, Schuppin GT et al (1995) Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non-insulindependent diabetes mellitus. J Clin Invest 95:1032–1039CrossRefPubMed

32.

Janson J, Ashley RH, Harrison D et al (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediatesized toxic amyloid particles. Diabetes 48:491–498CrossRefPubMed

33.

Butler AE, Janson J, Soeller WC et al (2003) Increased β-cell apoptosis prevents adaptive increase in β-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52:2304–2314CrossRefPubMed

34.

Demuro A, Mina E, Kayed R et al (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280:17294–17300CrossRefPubMed

35.

Skovronsky DM, Lee VM-Y, Trojanowski JQ (2006) Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol Mech Dis 1:151–170CrossRef

36.

Paulsson JF, Westermark GT (2005) Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation. Diabetes 54(7):2117–2125CrossRefPubMed

Titel: Serum levels of proamylin and amylin in normal subjects and patients with impaired glucose regulation and type 2 diabetes mellitus
verfasst von: Xiaoya Zheng
Wei Ren
Suhua Zhang
Jingjing Liu
Sufang Li
Jinchao Li
Ping Yang
Jun He
Shaochu Su
Ping Li
Publikationsdatum: 01.09.2010
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 3/2010
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-010-0201-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

OCT is not useful for detection of minimal diabetic retinopathy in type 1 diabetes

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

Independent factors associated with depression in type 1 diabetes mellitus

Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance

Association of obesity with diabetic retinopathy: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS Report no. 8)